- p18^INK4c, encoded by the CDKN2C gene, is a member of the INK4 family of cyclin‑dependent kinase inhibitors, alongside p16^INK4a, p15^INK4b, and p19^INK4d. Like other INK4 proteins, p18 specifically inhibits CDK4 and CDK6, preventing their association with cyclin D and thereby blocking phosphorylation of the retinoblastoma protein (Rb). Through this mechanism, p18 enforces a G₁‑phase arrest and ensures that cells do not prematurely enter S phase. Its activity is essential for maintaining controlled proliferation, supporting differentiation, and preserving tissue homeostasis.
- p18^INK4c plays a particularly important role in regulating cell‑cycle exit during differentiation. It is highly expressed in tissues where cells undergo terminal maturation, including the pancreas, nervous system, haematopoietic lineages, and skeletal muscle. In these contexts, p18 stabilises the withdrawal from the cell cycle, allowing cells to adopt specialised functions. This makes p18 a key coordinator of developmental timing, ensuring that proliferation slows as differentiation progresses. In contrast to p16, which is strongly induced by cellular stress and senescence, p18 is more closely associated with physiological growth control and lineage‑specific maturation.
- Regulation of p18 occurs at both transcriptional and post‑transcriptional levels. Developmental signalling pathways such as TGF‑β, BMP, and Notch influence p18 expression, linking extracellular cues to cell‑cycle restraint. Epigenetic mechanisms also contribute: promoter methylation or chromatin remodelling can suppress CDKN2C expression in certain cancers. Unlike p27^Kip1, which undergoes rapid ubiquitin‑mediated degradation via SCF^Skp2, p18 is relatively stable, and its abundance is primarily controlled by transcriptional regulation rather than proteasomal turnover. This stability ensures that once p18 is induced during differentiation, its inhibitory effects persist.
- Beyond its canonical role in CDK4/6 inhibition, p18 contributes to broader cellular functions. It helps maintain quiescence in stem‑cell populations, ensuring that proliferation is tightly regulated and preventing exhaustion of progenitor pools. In the immune system, p18 influences lymphocyte development by modulating proliferation thresholds during maturation. In endocrine tissues, p18 contributes to pancreatic β‑cell development and function, linking cell‑cycle control to metabolic regulation. These diverse roles highlight p18’s importance in coordinating proliferation with specialised physiological demands.
- Dysregulation of p18 has significant implications for human disease. Loss of CDKN2C expression is observed in multiple cancers, including pituitary tumours, leukaemias, lymphomas, and breast cancer. Reduced p18 levels remove a critical brake on CDK4/6 activity, allowing excessive Rb phosphorylation and uncontrolled entry into S phase. Conversely, inappropriate overexpression of p18 can impair tissue regeneration or contribute to degenerative conditions by enforcing excessive cell‑cycle arrest. Because p18 lies upstream of the Rb pathway, its status influences tumour behaviour and therapeutic response, particularly to CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib.
- In summary, p18^INK4c is a crucial regulator of G₁‑phase progression, differentiation, and tissue homeostasis. Its selective inhibition of CDK4/6, stable expression during maturation, and involvement in developmental and physiological processes distinguish it from other INK4 family members. Understanding p18 biology provides insight into cell‑cycle control, oncogenesis, and therapeutic strategies targeting the Rb pathway.
